Oncotelic Therapeutics, Inc.
OTLC
$0.04
$0.001.27%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 693.14% | 54.71% | -30.09% | -42.82% | -34.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 694.12% | 50.53% | -35.44% | -46.09% | -44.02% |
| Operating Income | -694.12% | -50.53% | 22.99% | 38.61% | 37.51% |
| Income Before Tax | 7,644.04% | 60.89% | -178.04% | 42.18% | 41.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5,310.16% | 60.89% | -178.04% | 42.18% | 41.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -0.23% | -1.44% | -3.98% | -11.88% | -15.65% |
| Net Income | 5,610.29% | 64.17% | -216.83% | 43.31% | 42.76% |
| EBIT | -694.12% | -50.53% | 22.99% | 38.61% | 37.51% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 5,189.19% | 65.81% | -190.91% | 45.73% | 45.05% |
| Normalized Basic EPS | -164.71% | -43.75% | 18.18% | 5.56% | 22.73% |
| EPS Diluted | 5,188.29% | 64.96% | -193.94% | 45.73% | 45.05% |
| Normalized Diluted EPS | -170.59% | -50.00% | 9.09% | 5.56% | 22.73% |
| Average Basic Shares Outstanding | 4.20% | 5.81% | 5.23% | 5.28% | 5.24% |
| Average Diluted Shares Outstanding | 6.95% | 8.67% | 8.10% | 5.28% | 5.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |